Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Lanzinger, S; Laubner, K; Warncke, K; Mader, JK; Kummer, S; Boettcher, C; Biester, T; Galler, A; Klose, D; Holl, RW.
Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry.
J Diabetes. 2024; 16(11): e70028
Doi: 10.1111/1753-0407.70028
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Mader Julia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Individuals with maturity-onset diabetes of the young (MODY) are often misdiagnosed as type 1 or type 2 diabetes and receive inappropriate care. We aimed to investigate the characteristics and treatment of all MODY types in a multicenter, real-world setting. METHODS: Individuals with MODY from the diabetes prospective follow-up (DPV) registry were studied. We compared clinical parameters during the first year of diabetes and the most recent treatment year after MODY diagnosis. RESULTS: A total of 1640 individuals were identified with GCK-MODY (n = 941) and HNF1A-MODY (n = 417) as the most frequent types. Among these, 912 individuals were available with information during the first and the most recent treatment year (median duration of follow-up: 4.2 years [2.6-6.6]). Positive beta cell autoantibodies were present in 20.6% (15.2% IAA). Median age at diagnosis ranged from 9.9 years in GCK-MODY (Q1-Q3: 6.2-13.1 years) and INS-MODY (2.7-13.7 years) to 14.3 years (5.0-17.1) in KCNJ11-MODY. Frequency of oral antidiabetic agents (OAD) use increased and insulin decreased in HNF4A-MODY (OAD: 18% to 39%, insulin: 34% to 23%) and in HNF1A-MODY (OAD: 18% to 31%, insulin: 35% to 25%). ABCC8-MODY was characterized by a decrement in nonpharmacological treatment (26% to 16%) and "insulin only" treatment (53% to 42%), while the proportion of individuals treated with OAD but no insulin increased from 0% to 21%. CONCLUSIONS: Our results indicate that some teams caring for individuals with MODY are hesitant with regard to current recommendations. Registries are an essential source of information and provide a basis for discussing treatment guidelines for MODY.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Diabetes Mellitus, Type 2 - genetics, drug therapy, diagnosis
- Registries - statistics & numerical data
- Male - administration & dosage
- Female - administration & dosage
- Adolescent - administration & dosage
- Child - administration & dosage
- Hypoglycemic Agents - therapeutic use
- Hepatocyte Nuclear Factor 1-alpha - genetics
- Prospective Studies - administration & dosage
- Follow-Up Studies - administration & dosage
- Germinal Center Kinases - genetics
- Potassium Channels, Inwardly Rectifying - genetics
- Sulfonylurea Receptors - genetics
- Insulin - therapeutic use
- Hepatocyte Nuclear Factor 4 - genetics
- Find related publications in this database (Keywords)
- diabetes prospective follow-up (DPV) registry
- MODY
- monogenic diabetes
- oral antidiabetic drugs
- real-world data